Key Presentation by Outlook Therapeutics at Upcoming Webinar
Outlook Therapeutics, Inc. (NASDAQ: OTLK), a notable biopharmaceutical company known for its innovative approach in treating retinal diseases, has exciting news to share. The company has achieved remarkable milestones in the healthcare sector, particularly with its ophthalmic formulation of bevacizumab, a groundbreaking treatment geared towards addressing wet age-related macular degeneration (wet AMD). This innovative formulation has received necessary regulatory approvals in the European Union and the United Kingdom, making it a significant advancement in retinal therapy.
About the Presentation
Lawrence A. Kenyon, the Executive Vice President, CFO, and Interim CEO of Outlook Therapeutics, will take the stage at an engaging event known as LIVE! with Webull Corporate Connect: Healthcare Investment Webinar. This anticipated presentation is scheduled for January 29, 2025, at 2:00 PM ET. Kenyon aims to provide insights about the company’s strategic direction, product development, and its innovative treatment that is set to launch commercially in the EU and UK.
Event Details and Registration
The healthcare investment webinar is designed to connect innovative biotech companies with potential investors aiming to make informed decisions. As part of the presentation, participants will gain access to critical information about how Outlook Therapeutics is positioning itself within the competitive biotech landscape.
How to Attend
For those interested in attending this informative session, registration is necessary. Interested parties can find the registration details through the official channels related to the event. This webinar represents a fantastic opportunity for stakeholders and investors to understand better the advancements in biotech and the value Outlook Therapeutics brings to the table.
About Outlook Therapeutics and Their Innovations
Outlook Therapeutics has established itself as a leader in the biopharmaceutical industry, particularly in the development of ONS-5010/LYTENAVA™ (bevacizumab-vikg). This formulation is specifically crafted for treating retinal diseases such as wet AMD. The drug is notably the first ophthalmic version of bevacizumab authorized by the European Commission and the UK's MHRA, aiming to set a new standard in retinal treatment.
Looking Ahead
With the projected commercial launch of LYTENAVA™ in the first half of the upcoming calendar year, Outlook Therapeutics is diligently preparing to make this innovative treatment available to patients suffering from wet AMD. In the United States, ONS-5010 is currently investigational, undergoing a non-inferiority study, which could lead to a Biologics License Application (BLA) resubmission to the FDA if successful. Securing FDA approval would position ONS-5010/LYTENAVA™ as the pioneering ophthalmic formulation of bevacizumab in the U.S. market.
Corporate Commitment to Patient Care
Outlook Therapeutics remains intensely focused on addressing unmet medical needs in the field of retinal diseases. The company’s commitment to patient care is evident through its rigorous scientific research and development initiatives aimed at providing effective solutions for challenging health issues. It recognizes the plight of those affected by conditions such as wet AMD and strives to deliver treatments that enhance patient outcomes significantly.
Investor Support and Communication
The company values communication and transparency with its investors. For any inquiries related to investments or corporate affairs, Jenene Thomas, the Chief Executive Officer of JTC Team, LLC, is available to assist. Contact details are provided for direct communication, highlighting the company’s commitment to investor relations.
Frequently Asked Questions
What is Outlook Therapeutics' main product?
Outlook Therapeutics’ main product is ONS-5010/LYTENAVA™ (bevacizumab-vikg), designed for the treatment of ocular diseases, especially wet AMD.
When is the upcoming webinar scheduled?
The webinar is scheduled for January 29, 2025, at 2:00 PM ET.
How can I register for the webinar?
Registration details will be available on the official event channels, ensuring interested participants can secure their spot.
What regulatory approvals has Outlook Therapeutics received?
The company has received regulatory approval for its ophthalmic formulation of bevacizumab in the EU and the UK.
What is the significance of the FDA's involvement?
The FDA's involvement is crucial as it signifies the potential for marketing and administering the treatment for wet AMD in the United States, enhancing access for patients.
